标题
Molecular tumour boards — current and future considerations for precision oncology
作者
关键词
-
出版物
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-10-16
DOI
10.1038/s41571-023-00824-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study
- (2023) A. Bayle et al. ANNALS OF ONCOLOGY
- Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164
- (2023) Dung T. Le et al. EUROPEAN JOURNAL OF CANCER
- Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study
- (2023) Wassim Abida et al. EUROPEAN UROLOGY
- Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
- (2023) Hideko Yamauchi et al. Breast Cancer
- Long-read sequencing identifies novel structural variations in colorectal cancer
- (2023) Luming Xu et al. PLoS Genetics
- Precision Oncology: Evolving Clinical Trials across Tumor Types
- (2023) I-Wen Song et al. Cancers
- Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study
- (2023) Ana Oaknin et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
- (2022) David M. O'Malley et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients
- (2022) Hong Zong et al. Journal of Cancer
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study
- (2022) Ana Oaknin et al. Journal for ImmunoTherapy of Cancer
- The TP53 Database: transition from the International Agency for Research on Cancer to the US National Cancer Institute
- (2022) Kelvin César de Andrade et al. CELL DEATH AND DIFFERENTIATION
- Patient attendance at molecular tumor board: A new means of shared decision making?
- (2022) Timothy Lewis Cannon et al. CURRENT PROBLEMS IN CANCER
- Delivering precision oncology to patients with cancer
- (2022) Joaquin Mateo et al. NATURE MEDICINE
- Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards
- (2022) Tara M. Love et al. PLoS One
- Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study
- (2022) M. Maio et al. ANNALS OF ONCOLOGY
- Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
- (2022) Kathrin Heinrich et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2022) Hedy L. Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Increasing targeted therapy options for patients with relapsed cancer with broader somatic gene panel analysis from the primary tumor: The Profiler02 randomized phase II trial.
- (2022) Olivier Tredan et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
- (2022) John Hilton et al. Nature Communications
- PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment
- (2022) J. Thouvenin et al. ESMO Open
- OncoPubMiner: a platform for mining oncology publications
- (2022) Quan Xu et al. BRIEFINGS IN BIOINFORMATICS
- Gene fusion detection and characterization in long-read cancer transcriptome sequencing data with FusionSeeker
- (2022) Yu Chen et al. CANCER RESEARCH
- Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA
- (2022) Nobuaki Matsubara et al. CLINICAL CANCER RESEARCH
- Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
- (2022) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
- (2022) Paul DiSilvestro et al. JOURNAL OF CLINICAL ONCOLOGY
- A Novel Bead-Capture Nanopore Sequencing Method for Large Structural Rearrangement Detection in Cancer
- (2022) Chloe L. Fisher et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Genomics to select treatment for patients with metastatic breast cancer
- (2022) Fabrice Andre et al. NATURE
- Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
- (2022) Henry Hiep Vo et al. npj Precision Oncology
- Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancer
- (2022) Takayuki Yoshino et al. CANCER SCIENCE
- Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans
- (2022) Linda D. Bosserman et al. Journal of Clinical Medicine
- Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing
- (2021) Nisha S. Ramani et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
- (2021) Anja Irmisch et al. CANCER CELL
- Liquid biopsy enters the clinic — implementation issues and future challenges
- (2021) Michail Ignatiadis et al. Nature Reviews Clinical Oncology
- Use of a clinical trial screening tool to enhance patient accrual
- (2021) Diane C. St. Germain et al. CANCER
- Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement
- (2021) Edward S. Kim et al. CLINICAL CANCER RESEARCH
- Global Precision Oncology: A Call to Action on Expanding Access to Targeted Cancer Therapies
- (2021) Maheetha Bharadwaj et al. ONCOLOGIST
- Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
- (2021) Ajjai S. Alva et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- (2021) Andrés Poveda et al. LANCET ONCOLOGY
- Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study
- (2021) Apostolia Maria Tsimberidou et al. npj Precision Oncology
- Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer
- (2021) Apostolia-Maria Tsimberidou et al. Journal of Hematology & Oncology
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- (2021) Paul Nathan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Framework for Implementing and Tracking a Molecular Tumor Board at a National Cancer Institute–Designated Comprehensive Cancer Center
- (2021) Neha M. Jain et al. ONCOLOGIST
- Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology
- (2021) Frank P. Lin et al. npj Precision Oncology
- Artificial intelligence for the next generation of precision oncology
- (2021) Pedro J. Ballester et al. npj Precision Oncology
- Variant interpretation using population databases: Lessons from gnomAD
- (2021) Sanna Gudmundsson et al. HUMAN MUTATION
- First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
- (2021) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Susana Banerjee et al. LANCET ONCOLOGY
- Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfiLER trial
- (2021) Alice Bonneville-Levard et al. MEDICAL ONCOLOGY
- Digital twins for predictive oncology will be a paradigm shift for precision cancer care
- (2021) Tina Hernandez-Boussard et al. NATURE MEDICINE
- The molecular tumor board: a tool for the governance of precision oncology in the real world
- (2021) Lorena Incorvaia et al. TUMORI
- Genomic landscape and clinical utility of Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program
- (2021) Kyong Hwa Park et al. Cancer Discovery
- Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
- (2021) Disha Malani et al. Cancer Discovery
- Cost‑effectiveness of precision cancer medicine‑current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review)
- (2021) Konstantinos Christofyllakis et al. Molecular and Clinical Oncology
- Molecular-based precision oncology clinical decision making augmented by artificial intelligence
- (2021) Jia Zeng et al. Emerging Topics in Life Sciences
- Support of a molecular tumour board by an evidence-based decision management system for precision oncology
- (2020) Mario Lamping et al. EUROPEAN JOURNAL OF CANCER
- THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN
- (2020) Keith T Flaherty et al. JNCI-Journal of the National Cancer Institute
- Circulating tumor DNA analysis in the era of precision oncology
- (2020) Rabih Said et al. Oncotarget
- Molecular profiling for precision cancer therapies
- (2020) Eoghan R. Malone et al. Genome Medicine
- Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
- (2020) Jonathan A Ledermann et al. LANCET ONCOLOGY
- Clinical significance of clonal hematopoiesis in the interpretation of blood liquid biopsy
- (2020) Hiu Ting Chan et al. Molecular Oncology
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
- (2020) Seock-Ah Im et al. Scientific Reports
- OncoPDSS: an evidence-based clinical decision support system for oncology pharmacotherapy at the individual level
- (2020) Quan Xu et al. BMC CANCER
- Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal
- (2020) David Tamborero et al. NATURE MEDICINE
- Cervical cancer in low and middle‑income countries (Review)
- (2020) Rodney Hull et al. Oncology Letters
- Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance
- (2020) Stephen J. Pettitt et al. Cancer Discovery
- A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
- (2020) L. Tobalina et al. ANNALS OF ONCOLOGY
- Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
- (2020) Keith T. Flaherty et al. JOURNAL OF CLINICAL ONCOLOGY
- “When offered to participate:” A systematic review and meta-analysis of patient agreement to participate in cancer clinical trials
- (2020) Joseph M Unger et al. JNCI-Journal of the National Cancer Institute
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
- (2020) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy
- (2020) Shumei Kato et al. Nature Communications
- Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer
- (2020) Ana Oaknin et al. JAMA Oncology
- Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
- (2020) Hiu Ting Chan et al. Cancers
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- UniProt: the universal protein knowledgebase in 2021
- (2020) et al. NUCLEIC ACIDS RESEARCH
- Survival Impact and Cost‐Effectiveness of a Multidisciplinary Tumor Board for Breast Cancer in Mozambique, Sub‐Saharan Africa
- (2020) Mariana Brandão et al. ONCOLOGIST
- Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference
- (2020) Kendal Jensen et al. JAMA Oncology
- Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
- (2019) O Trédan et al. ANNALS OF ONCOLOGY
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Variant classification in precision oncology
- (2019) Jonas Leichsenring et al. INTERNATIONAL JOURNAL OF CANCER
- Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
- (2019) Dominic G. Rothwell et al. NATURE MEDICINE
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
- (2019) Jordi Rodon et al. NATURE MEDICINE
- Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial
- (2019) Josep M. del Campo et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
- (2019) Alessandro Leonetti et al. BRITISH JOURNAL OF CANCER
- Tumor mutation burden: from comprehensive mutational screening to the clinic
- (2019) Francesca Galuppini et al. Cancer Cell International
- Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme
- (2019) Romain Varnier et al. EUROPEAN JOURNAL OF CANCER
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
- (2019) Pedram Razavi et al. NATURE MEDICINE
- Clonal hematopoiesis in human aging and disease
- (2019) Siddhartha Jaiswal et al. SCIENCE
- Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
- (2019) Apostolia-Maria Tsimberidou et al. Journal of Hematology & Oncology
- The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios
- (2018) Nicola Normanno et al. CANCER TREATMENT REVIEWS
- Clonal Hematopoiesis: A new layer in the liquid biopsy story in lung cancer
- (2018) Joshua Bauml et al. CLINICAL CANCER RESEARCH
- Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays
- (2018) Catherine C. Coombs et al. CLINICAL CANCER RESEARCH
- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- (2018) Oliver A. Zill et al. CLINICAL CANCER RESEARCH
- Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance
- (2018) Helena A. Yu et al. CLINICAL CANCER RESEARCH
- Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits
- (2018) Elena Fountzilas et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
- (2018) Jason D. Merker et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of DNA methylation in cancer: location revisited
- (2018) Alexander Koch et al. Nature Reviews Clinical Oncology
- A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2018) J Mateo et al. ANNALS OF ONCOLOGY
- The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer
- (2018) Smadar Laufer-Geva et al. Journal of Thoracic Oncology
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2
- (2018) Melissa S. Cline et al. PLoS Genetics
- Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
- (2017) Lawrence J. Jennings et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors
- (2017) Rajyalakshmi Luthra et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
- (2017) Chih-Jian Lih et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- (2017) Marilyn M. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Cervical cancer prevention and treatment in Latin America
- (2017) Melissa S. Lopez et al. JOURNAL OF SURGICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- ClinVar: improving access to variant interpretations and supporting evidence
- (2017) Melissa J Landrum et al. NUCLEIC ACIDS RESEARCH
- Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
- (2017) Ken Uchibori et al. Nature Communications
- Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors
- (2016) Rashmi S. Goswami et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- The evolving role of microsatellite instability in colorectal cancer: A review
- (2016) Fabio Gelsomino et al. CANCER TREATMENT REVIEWS
- Oncologic Care and Pathology Resources in Africa: Survey and Recommendations
- (2016) Ann M. Nelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer
- (2016) Haa-Na Song et al. Journal of Thoracic Oncology
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Polyclonal SecondaryFGFR2Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
- (2016) Lipika Goyal et al. Cancer Discovery
- Multiplexed Epitope-Based Tissue Imaging for Discovery and Healthcare Applications
- (2016) Bernd Bodenmiller Cell Systems
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform
- (2015) Amber Johnson et al. DRUG DISCOVERY TODAY
- Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?
- (2015) Jiri Polivka et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- (2015) Sue Richards et al. GENETICS IN MEDICINE
- Achieving Effective Universal Health Coverage And Diagonal Approaches To Care For Chronic Illnesses
- (2015) Felicia Marie Knaul et al. HEALTH AFFAIRS
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- A global reference for human genetic variation
- (2015) Richard A. Gibbs et al. NATURE
- All aboard: Will molecular tumor boards help cancer patients?
- (2015) Jeanne Erdmann NATURE MEDICINE
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
- (2015) Kenneth S Thress et al. NATURE MEDICINE
- A Decision Support Framework for Genomically Informed Investigational Cancer Therapy
- (2015) Funda Meric-Bernstam et al. JNCI-Journal of the National Cancer Institute
- Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor
- (2015) Helena A. Yu et al. JAMA Oncology
- Prioritizing targets for precision cancer medicine
- (2014) F. Andre et al. ANNALS OF ONCOLOGY
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types
- (2014) Ronald Lebofsky et al. Molecular Oncology
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- (2014) Eliezer M Van Allen et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Analysis for Therapy Choice: NCI MATCH
- (2014) Barbara A. Conley et al. SEMINARS IN ONCOLOGY
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- (2012) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- Microsatellite Instability in Colorectal Cancer
- (2010) C. Richard Boland et al. GASTROENTEROLOGY
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- (2010) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search